Xemperia SA

Novel blood based test for breast cancer detection.

XEMPERIA SA, is a science-driven startup spin-off from the University of Fribourg, Switzerland. Built on over 25 years of pioneering translational cancer research and biomarker discovery expertise.

Our Vision is to transform the future of cancer care through advanced blood testing.

Our Mission is to deliver innovative, accessible, and highly accurate blood tests for the early detection and monitoring of cancer-enhancing patient outcomes and reducing cancer-related mortality.

Our Solutions go beyond current methodologies that redefine whats possible in cancer diagnostics. Adaptable.

XEMPERIAs flagship solution is a blood test for early breast cancer detection to be offered yearly, to women at all ages as a first test in the breast cancer screening and diagnostic path.

Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
Milestone

28.02.2025

Second IP filed on the breast cancer blood test detectiongene signature

Milestone

01.01.2025

Publication on DNA nanosensor for mutation detection

Milestone

30.11.2024

GENOA clinical biomarker discovery study concluded

Milestone

29.10.2024

Awarded Innosuisse Core Coaching

Milestone

26.09.2024

Filed IP on RNA detection by DNA nanosensor

Show more...

No Jobs

Videos

Xemperia Presentation Video

https://www.youtube.com/watch?v=KgzdORaNOG8
Venture Kick

Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.

Website

Xemperia SA

Novel blood based test for breast cancer detection.

Headquarter:
Marly

Foundation Date:
December 2023

Technology:

  • Biotech

Sectors:

  • Cancer
  • Diagnostics
  • Medtech

Support received

  • Support venturekick